Shopping Cart

Unlocking a double locked polypail of Virgin Coconut Oil.............

Coconut oil and Covid 19 - the second coming?

Coconut oil and

Covid 19 - the second coming?

I’m not religious or even mildly biblical but…….


Even before I knew anything much about the current Covid 19 bizzo, I was asking myself this question……
“Is it possible for coconut oil to be effective against Covid 19 viral infections?”

You can see here, that people  far more qualified than me, have been asking the same question.

This is a link to work that is being completed in the Philippines on this very question.
“Can coconut oil help knock down Covid 19 infections?”

I started a business on importing the often vilified coconut oil / saturated fat back in 2006.

When keto and low carb diets took hold in around 2012 and 2013, that was like the first coming.  It was a complete and utter rejection of the bullshit we had been fed on saturated fat causing heart disease.

In yet another round, a second coming in fact – coconut oil may also prove to be a weapon in the fight against Covid infections.

How may coconut oil be effective against Covid 19 infections?

I have understood for 10 years that coconut oil can help knock down viral infections.

You can read here how I knocked down a norovirus infection 12 years ago.  I used simply coconut oil and pulverised ginger in a cup of hot water.

Viruses have a universal Achilles heel – they have a lipid shell or coating.
If this lipid shell is removed for any reason, the virus dies.
It is the monolaurin in coconut oil that provides the way for this to happen.

Or rather, the fact that the body converts coconut oil into monolaurin, a fatty acid.

What does monolaurin do to the lipid shell of a virus?

In short, monolaurin strips the lipid coating of a wide range of viruses and inactivates them.

This key finding was established in the 80’s and 90’s by a the brilliant scientific work of Dr Mary Enig, Jon Kabara and John Hierholzer

“Enig stated in her article that Monolaurin, of which the precursor is lauric acid, disrupted the lipid membranes of envelope viruses and also inactivated bacteria, yeast and fungi.

She wrote: “Of the saturated fatty acids, lauric acid has greater antiviral activity than either caprylic acid (C-10) or myristic acid (C-14). The action attributed to Monolaurin is that of solubilizing the lipids ..in the envelope of the virus causing the disintegration of the virus envelope.”

In India, coconut oil is fed to calves to treat Cryptosporidium as reported by Lark Lands Ph.D. in her upcoming book “Positively Well” (1).”
“While HHV-6A was not mentioned by Enig, HHV-6A is an enveloped virus and would be expected to disintegrate in the presence of lauric acid and/or Monolaurin.

Enig stated in her article that Monolaurin, of which the precursor is lauric acid, disrupted the lipid membranes of envelope viruses and also inactivated bacteria, yeast and fungi. She wrote:”Of the saturated fatty acids, lauric acid has greater antiviral activity than either caprylic acid (C-10) or myristic acid (C-14).

The action attributed to Monolaurin is that of solubilizing the lipids in the envelope of the virus causing the disintegration of the virus envelope.” I

n India, coconut oil is fed to calves to treat Cryptosporidium as reported by Lark Lands Ph.D. in her upcoming book “Positively Well” (1).”

Enig cites the references at the end of this article to support her contention that monolaurin or lauric acid, has the ability to shatter a wide range of viruses.

What to take?

Coconut oil or high quality coconut milk.

How much to take and what is a therapeutic dose?

Based on her calculations on the amount of lauric acid found in human Mother’s milk, Dr. Enig suggests a rich lauric acid diet would contain about 24 grams of lauric acid daily for the average adult.

This amount could be found in about 3.5 tablespoons of coconut oil or 10 ounces of “Pure Coconut Milk.” 

Mary Enig cites 24 references in her 7 page article on “Lauric Acid for HIV-infected Individuals,” a few of which are as follows:

References

  1. Issacs, C.E. et al. Inactivation of enveloped viruses in human bodily fluids by purified lipids. Annals of the New York Academy of Sciences 1994;724:457-464.
  1. Kabara, J.J. Antimicrobial agents derived from fatty acids. Journal of the American Oil Chemists Society 1984;61:397-403.
  1. Hierholzer, J.C. and Kabara J.J. In vitro effects on Monolaurin compounds on enveloped RNA and DNA viruses. Journal of Food Safety 1982;4:1-12.
  1. Wang, L.L. and Johnson, E.A. Inhibition of Listeria monocytogenes by fatty acids and monoglycerides. Appl Environ Microbiol 1992; 58:624-629.
  1. Issacs, C.E. et al. Membrane-disruptive effect of human milk: inactivation of enveloped viruses. Journal of Infectious Diseases 1986;154:966-971.
  1. Antiviral effects of monolaurin. JAQA 1987;2:4-6 7. Isaacs C.E. et al. Antiviral and antibacterial lipids in human milk and infant formula feeds. Archives of Disease in Childhood 1990;65:861-864.
 

posted 10-19-2004 08:20 AM         http://www.reciprocalnet.org/recipnet/showsample.jsp?sampleId=27343984

Lauric acid is found in vegetable oils such as cinnamon oil, butter, coconut oil, and palm oil.

Explanation: Lauric acid was first discovered in lauraceae seeds by Marsson T in 1849. The highest content of lauric acid is found in a mother’s breast milk and lauraceae seeds. It is used in foods such as vegetable shortenings as a defoaming agent and industrially as a booster for soaps and detergents. Also it is used in cosmetics, insecticides, and food additives. Additionally, Lauric acid is a medium chain fatty acid, which forms monolaurin in the human or animal body. This compound is an antiviral, antibacterial, and antiprotozoal monoglyceride that destroys lipid coated viruses such as HIV, herpes, cytomegalovirus, and influenza.

———————————— http://www.lauric.org/

March 5, 2001, lauric.org – The first clinical trial giving monolaurin in capsules at two levels (7.2 g (HML) and 2.4 g (LML)) or whole coconut oil (50 ml (CNO)) as a source of lauric acid (the precursor of monolaurin) to 15 HIV-infected patients took place in the San Lazaro Hospital, Manila, the Philippines under the charge of Dr. Eric Tayag, MD. The results of the trial were reported by Dr. Conrado S. Dayrit, MD, FACC, FPCC, FPCP on July 25, 2000 in Chennai, India at the 37th Cocotech Meeting. The patients, 10 females and 5 males, who were regularly being followed for their HIV status at the San Lazaro Hospital and had never received any anti-HIV treatment were divided into 3 treatment groups (HML, LML, CNO) of 5 patients each. The patients were seen daily with laboratory values determined at the beginning and the end of 3 months and 6 months. At onset of the trial, the viral load of the patients as measured by PCR, ranged from 1.96×103 to 1,190.0×103 copies. The CD4 and CD8 counts were measured by flow cytometry and at baseline they ranged from a low to a high, respectively, of 248 to 1065 and 570 to 1671. One male had a viral count too low to measure (< 0.4×103), which did not change, and he was not included in the final statistics. The final statistics included results for 4 males and 10 females and showed that 7 (2M, 5F) of 14 patients had a reduced load at 3 months and 8 (3M, 5F) of 14 patients had a reduced load at 6 months. The reduced viral load was significant in only 3 (2M,1F) patients using the log baseline minus log 6 months 0.5 criterion; 2 of the 3 were in the CNO group and one was in the LML group. The CD4 and CD8 levels increased in 5 patients but did not correlate exactly with a decrease in viral load. As a result of the encouraging responses in this small preliminary proof-of-concept trial, additional HIV-infected patients are being enrolled for a second larger and longer trial.

——————————————

(Comments: old study, small sample, but what I thought was interesting was that the oil seemed to be more effective than the derivative.)

———————————————– http://www.catie.ca/supple-e.nsf/0/9d416a2009131fd88525689e006c3f81?OpenDocument

Latest Blog